ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2024, Vol. 33 ›› Issue (5): 485-489.DOI: 10.3969/j.issn.1006-298X.2024.05.016

• 血液净化 • 上一篇    下一篇

细小脲原体所致腹膜透析相关腹膜炎

  

  • 出版日期:2024-10-28 发布日期:2024-11-01

Peritoneal dialysis associated peritonitis caused by ureaplasma parvum

  • Online:2024-10-28 Published:2024-11-01

摘要: 细小脲原体为一种支原体,属于正常菌群,定植在人体下生殖道,是腹膜透析相关腹膜炎少见病原体。细小脲原体不能通过革兰染色观察到或经由常规腹膜透析液培养检出,对目前腹膜炎常用一线及二线抗生素具有耐药性,抑制蛋白质合成和拓扑异构酶的药物是主要的治疗选择。宏基因组二代测序有助于及时明确病原体,调整治疗,改善患者预后。


关键词: 腹膜透析, 腹膜炎, 细小脲原体, 宏基因二代测序

Abstract: Ureaplasma parvum is a type of mycoplasma and part of the human microbiota,and can be isolated from both female and male genital tracts. It is a rare pathogen in peritoneal dialysis-associated peritonitis. Ureaplasma parvum cannot be detected by Gram staining or conventional peritoneal dialysis effluent cultures. It is resistant to the first-and second-line antibiotics commonly used for peritonitis. Drugs that inhibit protein synthesis and topoisomerase are the main treatment options. Metagenomic next-generation sequencing (mNGS) can help promptly identify the pathogen, adjust treatment, and improve patient outcomes.


Key words: peritoneal dialysis, peritonitis, ureaplasma parvum, metagenomics next-generation sequencing